KANEKA
31.3.2023 16:10:30 CEST | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005155/en/
(Figure 1) Recycling-oriented Biomanufacturing Technology (Graphic: Business Wire)
This project will contribute to the realization of carbon recycling in the "Green Growth Strategy Through Achieving Carbon Neutrality in 2050" formulated by the Ministry of Economy, Trade and Industry with related ministries and agencies on December 25, 2020 (revised on June 18, 2021). The goal of the project is to realize recycling-oriented biomanufacturing technology that does not depend on fossil resources by developing microorganisms that produce biodegradable polymers from CO2 and developing production process technology, combining the knowledge and technology that the four companies have cultivated over the years.
During the project period (FY2023 to FY2030), the following three themes will be addressed.
- Establishment of a gas fermentation biofoundry*2 using CO2 as a raw material (Bacchus and Shimadzu)
- Development and improvement of biopolymer-producing microorganisms (Kaneka)
- Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)
[ Kaneka ] https://www.kaneka.co.jp/en/
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the synthetic microbiology and polymer production, processing technologies it has cultivated to date, Kaneka will develop new microorganisms that produce Green Planet directly from CO2, and will also launch a semi-commercial plant to conduct production demonstration for Green Planet industrialization. In addition, we will lead this project as the managing company.
[ Bacchus ] https://www.b2i.co.jp/
Bacchus is a data-driven biofoundry company. Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies. By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species. In addition, they will introduce and utilize data from a high-throughput evaluation system jointly developed with Shimadzu, and aim to build an "Integrated Biofoundry*4" that will provide one-stop service from microbial breeding to process development with JGC HD.
[ JGC HD ] https://www.jgc.com/en/
JGC HD has a profound knowledge of the safe gas handling of gases including hydrogen gas and process scale-up cultivated through its EPC (Engineering, Procurement, and Construction) business in the oil and gas fields, as well as in optimized culture tank design technology in the life science field. In this project, JGC HD will develop and scale-up a safe handling system for mixed gases containing CO2, H2, and O2 and a highly efficient gas fermentation process in addition to establishing an “Integrated Biofoundry” with Bacchus which will provide a one-stop service from microbial breeding to process development.
[ Shimadzu ] https://www.shimadzu.com/
Shimadzu, with the aim of solving social issues, has accumulated a variety of know-how by providing analytical measurement and robotics technologies to a wide range of fields and data analysis technologies using AI-based systems. In this project, Shimadzu will work on the development of high-speed productivity evaluation technology, which is indispensable for the construction of a biofoundry. Shimadzu will also develop an evaluation system to measure gas fermentation in the semi-commercial plant which is to be constructed as part of the project and support safe and highly efficient fermentation.
*1. A project to support companies and others working on management issues toward Japan's "Carbon Neutrality in 2050," from R&D and demonstration to social implementation by FY2030. The program covers 14 fields: transportation/manufacturing-related industries including carbon recycling/materials industries, energy-related industries, and home/office-related industries.
*2. Biofoundry: Microorganism development platform that creates microorganisms with designed functions to efficiently produce useful substances
*3. Smart cell: A cell that is highly designed and has an enhanced ability to efficiently produce the desired substance
*4. Integrated Biofoundry: A one-stop biomanufacturing platform that provides everything from microbial breeding to process development
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005155/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom